Composition and methods for treatment of lung disorders characterized by cholesterol dysregulation
US10251852B2 · kind B2 · utility
0Cited by
0References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 11, 2017 |
| Grant date | Apr 9, 2019 |
| Priority date | — |
| Expiry date | Apr 11, 2037 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K47/26
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are compositions and methods for treating a condition characterized by a dysregulation in macrophage lipid homeostasis. The disclosed methods may include the administration of an agent selected from a PPARγ agonist, a LXR agonist, or a combination thereof. In certain aspects, the disclosed methods may be used to prevent, treat, or ameliorate conditions such as pulmonary alveolar proteinosis (PAP) and/or symptoms associated therewith.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.